• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Egetis Therapeutics

5.63 SEK

-8.46 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-8.46 %
-11.06 %
+5.83 %
+5.43 %
+6.23 %
+30.32 %
+13.74 %
+8.99 %
-59.31 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.76B SEK
Turnover
6.22M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8
2026

Interim report Q2'26

6.11
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release10.06.2026, 15.00

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Egetis Therapeutics
Regulatory press release29.05.2026, 10.00

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Press release19.05.2026, 14.00

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release13.05.2026, 16.45

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics
Press release07.05.2026, 10.00

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics
Press release05.05.2026, 08.00

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Egetis Therapeutics
Press release30.04.2026, 12.30

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Regulatory press release30.04.2026, 09.05

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q1'26
Webcast29.04.2026, 10.00

Egetis Therapeutics, Audiocast, Q1'26

Egetis Therapeutics
Regulatory press release29.04.2026, 07.00

Interim report Q1 2026

Egetis Therapeutics
Press release24.04.2026, 11.00

Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026

Egetis Therapeutics
Regulatory press release21.04.2026, 22.57

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release21.04.2026, 17.31

Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)

Egetis Therapeutics
Regulatory press release14.04.2026, 15.45

Bulletin from Egetis Therapeutics’ Annual General Meeting 2026

Egetis Therapeutics
Press release09.04.2026, 07.00

Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics
Press release08.04.2026, 13.20

Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®

Egetis Therapeutics
Regulatory press release27.03.2026, 16.42

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency

Egetis Therapeutics
Regulatory press release24.03.2026, 15.05

Egetis Therapeutics’ Annual Report 2025 published

Egetis Therapeutics
Regulatory press release12.03.2026, 12.02

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Egetis Therapeutics
Press release09.03.2026, 07.00

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics